By Sophora Health Editorial Team  ·  Medically reviewed  ·  Published July 2026  ·  Last reviewed July 2026

Imagine your pituitary gland sending a message to your ovaries: produce more oestrogen, please. The ovaries receive the message, oblige, and send confirmation back. This has been happening reliably every cycle since puberty. During perimenopause, the ovaries start responding less reliably. So the pituitary sends the message louder. Then louder still. The messages pile up, unread. The pituitary, now increasingly anxious, keeps escalating. FSH and LH are those messages. By the time FSH and LH are elevated enough to show up on a blood test, the pituitary has been shouting into a room where the ovaries are wearing headphones for quite some time.

What are FSH and LH, and why do they matter in perimenopause?

FSH: the follicle-stimulating hormone

FSH’s primary job is to stimulate the ovarian follicles to develop and produce oestrogen each cycle. In a regular cycle, FSH rises in the first half, stimulates follicle development, and falls once oestrogen rises high enough to signal back to the pituitary that the job is done. This feedback loop has been running smoothly since puberty.

During perimenopause, the ovarian follicles become less responsive. Fewer of them remain, and those that do require more stimulation to produce the same amount of oestrogen. So the pituitary produces more FSH. As perimenopause progresses, FSH levels rise progressively, starting in the early 40s in many women, years before oestrogen levels fall significantly.

This timing matters enormously. FSH begins rising before oestrogen drops. Research shows that bone loss starts 2 to 3 years before the final menstrual period, at a time when oestrogen is still relatively normal but FSH is already elevated. This suggests FSH may be directly contributing to bone loss, not just serving as a marker of oestrogen decline. FSH receptors have been found in osteoclasts, the cells that break bone down, and in endothelial cells that line blood vessels. The pituitary’s escalating distress signal is doing things in the body beyond its original brief.

Higher FSH levels in postmenopause have been linked to decreased bone mineral density, higher LDL cholesterol, and mild cognitive impairment. There is also a paradox: higher FSH is associated with increased insulin sensitivity and lower risk of metabolic syndrome, which researchers are still working to understand fully. FSH in midlife turns out to be considerably more interesting than the simple diagnostic marker it is usually treated as.

LH: the luteinising hormone

LH’s primary job is to trigger ovulation. Mid-cycle, when the dominant follicle is ready, LH surges sharply. This is the LH surge that ovulation predictor kits detect. The egg is released. The follicle becomes the corpus luteum, which then produces progesterone for the second half of the cycle.

During perimenopause, the LH surge becomes erratic. It can fire at the wrong time, or fire without an egg actually being released. You can get a positive ovulation predictor result and not ovulate, which means no corpus luteum forms and no progesterone is produced that cycle. This is one of the structural reasons progesterone declines first during perimenopause. LH is sending the signal. The machinery to respond to it is becoming unreliable.

LH also rises as perimenopause progresses, though not as dramatically as FSH. After menopause, both reach their highest levels, higher than at any point in a regular cycle, including higher than during the normal mid-cycle surge. The pituitary does not give up easily.

FSH and LH rising is not a failure. It is your pituitary doing exactly what it was designed to do, which is to keep trying. The ovaries are not failing to respond because anything is wrong. The transition is working exactly as biology intended. Your pituitary just has not got the memo yet.

Someone important to you needs this too.

WhatsAppiMessageCopy LinkEmail

The testing problem: why a single reading tells you very little

FSH and LH fluctuate dramatically across the menstrual cycle and even more dramatically during perimenopause. A single blood test taken at a random point in the cycle can show values that are completely different from a test taken five days later. This makes them poor diagnostic tools in isolation during the perimenopausal years.

An FSH above 25 mIU/mL alongside irregular periods suggests the transition is underway. An FSH consistently above 30 mIU/mL, confirmed on two or more separate readings, is generally considered indicative of menopause, particularly alongside 12 consecutive months without a period. A single reading, however dramatic, proves very little during perimenopause when the whole point is that levels are fluctuating.

This is why clinical guidelines consistently note that symptoms, age, and menstrual history are more reliable indicators of where you are in the transition than a one-off hormone panel. The test can be confirmatory. It is rarely conclusive on its own.

LH is even less diagnostically useful than FSH during this period. A positive LH surge on an ovulation predictor kit confirms a surge happened. It does not confirm that ovulation followed.

FSH, LH, and bone health: the finding most people miss

The connection between elevated FSH and bone density loss is one of the most important and least-discussed findings in perimenopause research. Because bone loss has traditionally been attributed to oestrogen decline, the standard clinical conversation about bone health during perimenopause tends to focus on oestrogen replacement. But bone loss begins before oestrogen falls, at a point when FSH is already elevated.

A SWAN analysis of 2,311 women across four ethnic groups found bone loss over four years was directly related to baseline FSH level, independently of oestrogen. A University of Lahore study of 180 postmenopausal women found that higher FSH was significantly associated with lower lumbar spine bone mineral density. Women in late menopause had FSH levels of 68.7 mIU/mL compared to 51.6 mIU/mL in earlier postmenopause, alongside markedly reduced bone density. FSH receptors on osteoclasts may mean that FSH itself, independent of oestrogen, is actively stimulating bone breakdown.

This does not change the practical advice around bone health: weight-bearing exercise, adequate calcium and vitamin D, and discussing HRT with a clinician where appropriate remain the key actions. It does reframe the mechanism, though. The risk to bone starts earlier than most people are told, driven partly by rising FSH rather than waiting for oestrogen to fall.

FSH and LH across populations

FSH and LH rise in every woman going through the menopausal transition, but the timing, the rate of rise, and the clinical consequences vary by ethnicity and context.

The Pan-Asia Menopause (PAM) study measured FSH and LH profiles across nine ethnic groups of postmenopausal Asian women. It found meaningful variation in both FSH and LH levels between groups, including Thai, Filipino, Indonesian, Malaysian, Taiwanese, Korean, Chinese, Hong Kong, and Singaporean women. This variation challenges the assumption that a single reference range applies universally across all populations.

SWAN data found the rate of FSH increase during the transition differed significantly between Hispanic and African American women compared to Caucasian women, with each group showing different hormonal trajectories. These differences affect when symptoms begin to be experienced, how the transition unfolds, and potentially how it responds to treatment.

In traditional medicine systems, the hormonal communication between brain and ovaries during this transition is framed through different but parallel concepts. Ayurvedic medicine understands the transition as a shift in prana, the vital life force. Shatavari and ashwagandha are used to support the nervous and endocrine systems through it. Traditional Chinese Medicine frames this as a disruption between kidney yin, which governs reproductive essence, and the broader hormonal system. Acupuncture and herbal formulas are used to regulate the signalling. African traditional medicine across multiple traditions has used adaptogenic plants to support hormonal resilience during midlife transitions. Vitex agnus-castus is particularly associated with cycle regulation in both West African and Mediterranean traditional contexts.

In many parts of the world, FSH and LH testing is not routinely available, and the menopausal transition is managed on the basis of symptoms and menstrual history alone. This is clinically appropriate, since a clinical history remains more informative than a single hormone panel during perimenopause. But it is sometimes a function of limited access rather than clinical choice. Women who cannot get tested are not receiving worse care for it in most cases.

What to do with a high FSH or LH result

A high FSH or LH on its own is the beginning of a conversation, not the end of one. Here is what to do with it practically.

If FSH is elevated on a single reading and you are still having periods: get a second reading at a different point in the cycle. Compare with symptoms and menstrual history. A single elevated result during perimenopause is not clinically meaningful on its own.

If FSH is consistently elevated above 30 mIU/mL and periods have been absent for 12 months: this confirms menopause. Use this as the prompt to discuss bone health specifically with your doctor, because the bone loss has been underway longer than you may have been told.

If you have been using ovulation predictor kits to avoid or plan pregnancy: a positive result during perimenopause does not confirm ovulation. Progesterone testing seven days after the presumed surge is needed to confirm whether ovulation actually occurred.

Sophora’s Doctor Prep document can help you bring an organised account of your FSH and LH results, your symptoms, and your menstrual history to a clinical appointment. The conversation starts with a complete picture, not a number on a page.

Questions you are probably asking

My FSH is high. Does that mean I am in menopause?

A single elevated FSH does not confirm menopause, particularly during perimenopause when levels fluctuate widely. A consistent FSH above 30 mIU/mL on at least two separate readings, combined with 12 months without a period, is the clinical standard for confirming menopause. One result is a data point. Two or more results over time with symptom context is a diagnosis.

Why do FSH and LH rise in perimenopause?

Because the pituitary is responding to the ovaries becoming less responsive. As follicle numbers decline and oestrogen production becomes less reliable, the pituitary sends higher and higher levels of FSH and LH to try to stimulate the ovaries. The rise in FSH and LH is the pituitary doing exactly what it was designed to do when the ovaries are winding down. That is not a problem.

Can FSH and LH cause symptoms directly?

Emerging research suggests FSH may contribute directly to bone loss and cardiovascular changes, independently of oestrogen decline. The bone loss finding is the most clinically significant and best-evidenced of these extragonadal effects. For most symptomatic experiences during perimenopause, oestrogen and progesterone fluctuation remain the primary drivers. But FSH is no longer considered just a passive marker.

Do I need to test FSH and LH?

For diagnosing perimenopause, probably not. Your symptoms and menstrual history are more informative than a single blood test during this period. Testing is most useful for confirming postmenopause, ruling out other causes such as thyroid dysfunction, or confirming early menopause in women under 45 where specific management is needed.

Someone important to you needs this too.

WhatsAppiMessageCopy LinkEmail

FSH and LH rising is not a failure. It is your pituitary doing exactly what it was designed to do. The ovaries are not failing to respond because anything is wrong. The transition is working exactly as biology intended. Your pituitary just has not got the memo yet.

Last reviewed: July 2026  ·  Review due: September 2026  ·  Not therapy. Not medical advice. For your own use and understanding only.  ·  mysophora.com